Clinical Trial Update: Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and brain function of two doses of PF-0254920 in early Huntington's disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• PF-0254920

Snippet

Sponsor: Pfizer | Conditions: Huntington's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-12-14